BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, Kim C, Chernyak V, Yokoo T, Meyer J, Newton I, Do RK. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018;43:218-30. [PMID: 28780679 DOI: 10.1007/s00261-017-1281-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 13.8] [Reference Citation Analysis]
Number Citing Articles
1 Coleman A, Smith EN, J. Galgano S, Porter KK. Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00010-0] [Reference Citation Analysis]
2 Peng W, Jiang X, Zhang W, Hu J, Zhang Y, Zhang L. A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation. Asian Journal of Surgery 2022. [DOI: 10.1016/j.asjsur.2022.09.130] [Reference Citation Analysis]
3 Saghafian Larijani R, Shabani Ravari N, Goodarzi N, Akhlaghpour S, Saghafian Larijani S, Rouini MR, Dinarvand R. Current status of transarterial chemoembolization (TACE) agents in hepatocellular carcinoma treatment. Journal of Drug Delivery Science and Technology 2022;77:103905. [DOI: 10.1016/j.jddst.2022.103905] [Reference Citation Analysis]
4 Horvat N, de Oliveira AI, Clemente de Oliveira B, Araujo-Filho JAB, El Homsi M, Elsakka A, Bajwa R, Martins GLP, Elsayes KM, Menezes MR. Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists. Radiographics 2022;42:1670-89. [PMID: 36190854 DOI: 10.1148/rg.220022] [Reference Citation Analysis]
5 Chartampilas E, Rafailidis V, Georgopoulou V, Kalarakis G, Hatzidakis A, Prassopoulos P. Current Imaging Diagnosis of Hepatocellular Carcinoma. Cancers 2022;14:3997. [DOI: 10.3390/cancers14163997] [Reference Citation Analysis]
6 Wu Q, Chen Y, Du S, Hu Y, Yang P, Zeng Z. Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy. Clinical and Translational Radiation Oncology 2022. [DOI: 10.1016/j.ctro.2022.03.010] [Reference Citation Analysis]
7 Seo N, Joo DJ, Park MS, Kim SS, Shin HJ, Chung YE, Choi JY, Kim MS, Kim MJ. Optimal imaging criteria and modality to determine Milan criteria for the prediction of post-transplant HCC recurrence after locoregional treatment. Eur Radiol 2022. [PMID: 35821427 DOI: 10.1007/s00330-022-08977-z] [Reference Citation Analysis]
8 De Muzio F, Grassi F, Dell’aversana F, Fusco R, Danti G, Flammia F, Chiti G, Valeri T, Agostini A, Palumbo P, Bruno F, Cutolo C, Grassi R, Simonetti I, Giovagnoni A, Miele V, Barile A, Granata V. A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. Diagnostics 2022;12:1655. [DOI: 10.3390/diagnostics12071655] [Reference Citation Analysis]
9 Abdelrahman AS, Ekladious MEY, Badran EM, Madkour SS. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response. Diagn Interv Imaging 2022:S2211-5684(22)00118-8. [PMID: 35787988 DOI: 10.1016/j.diii.2022.06.007] [Reference Citation Analysis]
10 Alnammi M, Wortman J, Therrien J, Afnan J. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol (NY) 2022;47:2299-313. [PMID: 35524803 DOI: 10.1007/s00261-022-03526-0] [Reference Citation Analysis]
11 Borde T, Nezami N, Gaupp FL, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022;:212426. [PMID: 35412368 DOI: 10.1148/radiol.212426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Tantawi M, Shamimi-noori S, Shaw CM, Eisenbrey JR. State of the Art: Contrast Enhanced 4D Ultrasound to Monitor or Assess Locoregional Therapies. Digestive Disease Interventions 2022;06:003-012. [DOI: 10.1055/s-0041-1741520] [Reference Citation Analysis]
13 Bozzato AM, Martingano P, Pozzi Mucelli RA, Cavallaro MFM, Cesarotto M, Marcello C, Tiribelli C, Pascut D, Pizzolato R, Pozzi Mucelli F, Giuffrè M, Crocè LS, Cova MA. MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. Diagnostics 2022;12:374. [DOI: 10.3390/diagnostics12020374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Bartnik K, Podgórska J, Rosiak G, Korzeniowski K, Rowiński O. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization. Abdom Radiol (NY) 2022;47:115-22. [PMID: 34581927 DOI: 10.1007/s00261-021-03272-9] [Reference Citation Analysis]
15 Mahmoud BE, Gadalla AAEH, Elkholy SF. The role of dynamic and diffusion MR imaging in therapeutic response assessment after microwave ablation of hepatocellular carcinoma using LI-RADS v2018 treatment response algorithm. Egypt J Radiol Nucl Med 2021;52:60. [DOI: 10.1186/s43055-021-00428-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Elrefaey Hasan BM, Abd Elhamid HAE, Khater NH, Elgendy W, Abdelrahman AS. Role of DWI in evaluation of HCC after radiofrequency ablation compared to dynamic MRI using MRI (3 T). Egypt J Radiol Nucl Med 2021;52:267. [DOI: 10.1186/s43055-021-00647-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Li B, Xu A, Huang Y, Peng L, Xiang K, Li Q, Tang D, You H, Tan F, Wang N. Oxygen-Challenge Blood Oxygen Level-Dependent Magnetic Resonance Imaging for Evaluation of Early Change of Hepatocellular Carcinoma to Chemoembolization: A Feasibility Study. Acad Radiol 2021;28 Suppl 1:S13-9. [PMID: 32747180 DOI: 10.1016/j.acra.2020.06.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Mendiratta-Lala M, Aslam A, Maturen KE, Westerhoff M, Sun Y, Maurino C, Parikh ND, Sonnenday CJ, Stein EB, Shampain KL, Kaza RK, Cuneo K, Masch W, Do RKG, Lawrence TS, Owen D. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy with Radiologic-Pathologic Explant Correlation in patients with SBRT treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02902-3. [PMID: 34644607 DOI: 10.1016/j.ijrobp.2021.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Miller FH, Lopes Vendrami C, Gabr A, Horowitz JM, Kelahan LC, Riaz A, Salem R, Lewandowski RJ. Evolution of Radioembolization in Treatment of Hepatocellular Carcinoma: A Pictorial Review. Radiographics 2021;41:1802-18. [PMID: 34559587 DOI: 10.1148/rg.2021210014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
20 Kim TH, Woo S, Joo I, Bashir MR, Park MS, Burke LMB, Mendiratta-Lala M, Do RKG. LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data. Abdom Radiol (NY) 2021;46:3717-28. [PMID: 34027566 DOI: 10.1007/s00261-021-03122-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
21 Ormiston WEL, Yarmohammadi H, Lobaugh S, Schilsky J, Katz SS, LaGratta M, Velayati S, Zheng J, Capanu M, Do RKG. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization. Abdom Radiol (NY) 2021;46:3738-47. [PMID: 32968863 DOI: 10.1007/s00261-020-02775-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Shampain KL, Hackett CE, Towfighi S, Aslam A, Masch WR, Harris AC, Chang SD, Khanna K, Mendiratta V, Gabr AM, Owen D, Mendiratta-Lala M. SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY) 2021;46:3615-24. [PMID: 33963419 DOI: 10.1007/s00261-021-03107-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
24 Spieler B, Sabottke C, Moawad AW, Gabr AM, Bashir MR, Do RKG, Yaghmai V, Rozenberg R, Gerena M, Yacoub J, Elsayes KM. Artificial intelligence in assessment of hepatocellular carcinoma treatment response. Abdom Radiol (NY) 2021;46:3660-71. [PMID: 33786653 DOI: 10.1007/s00261-021-03056-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Shenoy-Bhangle AS, Tsai LL, Masciocchi M, Arora SS, Kielar AZ. Role of the radiologist at HCC multidisciplinary conference and use of the LR-TR algorithm for improving workflow. Abdom Radiol (NY) 2021;46:3558-64. [PMID: 33904990 DOI: 10.1007/s00261-021-03094-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 M Cunha G, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, Marks RM, Cruite I, Horvat N, Chernyak V, Sirlin CB, Tang A. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics 2021;41:1352-67. [PMID: 34297631 DOI: 10.1148/rg.2021200205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Delaney LJ, Tantawi M, Wessner CE, Machado P, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Civan J, Tan A, Anton K, Shaw CM, Eisenbrey JR. Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences. Ultrasound Med Biol 2021;47:2523-31. [PMID: 34130880 DOI: 10.1016/j.ultrasmedbio.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Youn SY, Kim DH, Choi JI, Choi MH, Kim B, Shin YR, Oh SN, Rha SE. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI. Korean J Radiol 2021;22:1289-99. [PMID: 34047507 DOI: 10.3348/kjr.2020.1394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bajaj G, Sundaram K, Jambhekar K, Ram R. Imaging After Locoregional Therapy for Hepatocellular Carcinoma with Emphasis on LIRADS Treatment Response Assessment Criteria. Semin Ultrasound CT MR 2021;42:318-31. [PMID: 34130846 DOI: 10.1053/j.sult.2021.04.004] [Reference Citation Analysis]
30 Bae JS, Lee JM, Yoon JH, Kang HJ, Jeon SK, Joo I, Lee KB, Kim H. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI. Radiology 2021;299:336-45. [PMID: 33650901 DOI: 10.1148/radiol.2021203537] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
31 Huang Z, Zhou P, Li S, Li K. MR versus CEUS LI-RADS for Distinguishing Hepatocellular Carcinoma from other Hepatic Malignancies in High-Risk Patients. Ultrasound Med Biol 2021;47:1244-52. [PMID: 33610338 DOI: 10.1016/j.ultrasmedbio.2021.01.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lee J, Joo I, Lee DH, Jeon SK, Lee JM. Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:597-606. [PMID: 32812065 DOI: 10.1007/s00261-020-02707-z] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Youn SY, Kim DH, Choi SH, Kim B, Choi JI, Shin YR, Oh SN, Rha SE. Diagnostic performance of Liver Imaging Reporting and Data System treatment response algorithm: a systematic review and meta-analysis. Eur Radiol 2021;31:4785-93. [PMID: 33409795 DOI: 10.1007/s00330-020-07464-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
35 Cunha GM, Tamayo-Murillo DE, Fowler KJ. LI-RADS and transplantation: challenges and controversies. Abdom Radiol (NY) 2021;46:29-42. [PMID: 31696268 DOI: 10.1007/s00261-019-02311-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Aslam A, Do RKG, Chernyak V, Mendiratta-lala M. LI-RADS Imaging Criteria for HCC Diagnosis and Treatment: Emerging Evidence. Curr Hepatology Rep 2020;19:437-447. [DOI: 10.1007/s11901-020-00546-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
38 Mendiratta-Lala M, Masch W, Owen D, Aslam A, Maurino C, Devasia T, Schipper MJ, Parikh ND, Cuneo K, Lawrence TS, Davenport MS. Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol (NY) 2020;45:3698-708. [PMID: 32303772 DOI: 10.1007/s00261-020-02532-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
39 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
40 Amorim J, França M, Perez-Girbes A, Torregrosa A, Martí-Bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol (NY) 2020;45:3119-28. [PMID: 32173774 DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Park S, Joo I, Lee DH, Bae JS, Yoo J, Kim SW, Lee JM. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI. Radiology 2020;296:554-61. [DOI: 10.1148/radiol.2020192797] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
42 Abdel razek A, El-serougy L, Saleh G, Shabana W, Abd el-wahab R. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy. Diagnostic and Interventional Imaging 2020;101:547-53. [DOI: 10.1016/j.diii.2020.03.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
43 Do RK, Mendiratta-Lala M. Moving Away from Uncertainty: A Potential Role for Ancillary Features in LI-RADS Treatment Response. Radiology 2020;296:562-3. [PMID: 32697166 DOI: 10.1148/radiol.2020202637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Gupta P, Kalra N, Gulati A, Dev V, Gorsi U, Cheluvashetty SB, Kumar-m P, Duseja A, Singh V, Dhiman RK, Sandhu MS. Response Assessment Following Image-Guided Therapy of Hepatocellular Carcinoma. Journal of Clinical Interventional Radiology ISVIR 2020;4:088-97. [DOI: 10.1055/s-0040-1708579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
45 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Abdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd El-Wahab R. Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know. J Comput Assist Tomogr. 2020;44:168-177. [PMID: 32195795 DOI: 10.1097/rct.0000000000000995] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
47 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
48 Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transpl 2020;26:203-14. [PMID: 31677319 DOI: 10.1002/lt.25673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
49 Saleh TY, Bahig S, Shebrya N, Ahmed AY. Value of dynamic and DWI MRI in evaluation of HCC viability after TACE via LI-RADS v2018 diagnostic algorithm. Egypt J Radiol Nucl Med 2019;50. [DOI: 10.1186/s43055-019-0120-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
50 Voizard N, Cerny M, Assad A, Billiard JS, Olivié D, Perreault P, Kielar A, Do RKG, Yokoo T, Sirlin CB, Tang A. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging 2019;10:121. [PMID: 31853668 DOI: 10.1186/s13244-019-0801-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
51 Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, Ronald J, Commander L, Hertel J, Luo S, Bashir MR, Burke LMB. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology. 2020;294:320-326. [PMID: 31845843 DOI: 10.1148/radiol.2019191581] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
52 Do RK, Mendiratta-Lala M. LI-RADS Version 2018 Treatment Response Algorithm: The Evidence Is Accumulating. Radiology 2020;294:327-8. [PMID: 31846402 DOI: 10.1148/radiol.2020192484] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
53 Millet JD, Kamaya A, Choi HH, Dahiya N, Murphy PM, Naveed MZ, O’boyle M, Parra LA, Perez MG, Pirmoazen AM, Rodgers SK, Wasnik AP, Maturen KE. ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. Journal of the American College of Radiology 2019;16:1656-62. [DOI: 10.1016/j.jacr.2019.05.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
54 Seo N, Kim MS, Park MS, Choi JY, Do RKG, Han K, Kim MJ. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol. 2020;30:261-271. [PMID: 31418085 DOI: 10.1007/s00330-019-06376-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
55 Gervais DA. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology 2019;292:235-6. [DOI: 10.1148/radiol.2019190768] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
56 Thibodeau-Antonacci A, Petitclerc L, Gilbert G, Bilodeau L, Olivié D, Cerny M, Castel H, Turcotte S, Huet C, Perreault P, Soulez G, Chagnon M, Kadoury S, Tang A. Dynamic contrast-enhanced MRI to assess hepatocellular carcinoma response to Transarterial chemoembolization using LI-RADS criteria: A pilot study. Magn Reson Imaging 2019;62:78-86. [PMID: 31247250 DOI: 10.1016/j.mri.2019.06.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
57 Patella F, Pesapane F, Fumarola E, Zannoni S, Brambillasca P, Emili I, Costa G, Anderson V, Levy EB, Carrafiello G, Wood BJ. Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. Future Oncol 2019;15:1791-804. [PMID: 31044615 DOI: 10.2217/fon-2018-0747] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, King LY, Janas GL, Do RK, Kim CY, Ronald J, Bashir MR. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology. 2019;292:226-234. [PMID: 31038409 DOI: 10.1148/radiol.2019182135] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
59 Kamath A, Roudenko A, Hecht E, Sirlin C, Chernyak V, Fowler K, Mitchell DG. CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 2019;44:1306-22. [PMID: 30671612 DOI: 10.1007/s00261-018-1868-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
60 Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.J Hepatocell Carcinoma. 2019;6:49-69. [PMID: 30788336 DOI: 10.2147/JHC.S186239] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 16.5] [Reference Citation Analysis]
61 Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging 2019;10:8. [PMID: 30694398 DOI: 10.1186/s13244-019-0690-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
62 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
63 Yacoub JH, Elsayes KM, Fowler KJ, Hecht EM, Mitchell DG, Santillan C, Szklaruk J. Pitfalls in liver MRI: Technical approach to avoiding misdiagnosis and improving image quality: Pitfalls in Liver MRI: Technical Approach. J Magn Reson Imaging 2019;49:41-58. [DOI: 10.1002/jmri.26343] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
64 Lo EC, N. Rucker A, Federle MP. Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Imaging for Diagnosis, Tumor Response to Treatment and Liver Response to Radiation. Seminars in Radiation Oncology 2018;28:267-76. [DOI: 10.1016/j.semradonc.2018.06.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
65 Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, Marks RM, Cruite I, Fowler KJ, Tang A, Bashir MR, Hecht EM, Kamaya A, Jambhekar K, Kamath A, Arora S, Bijan B, Ash R, Kassam Z, Chaudhry H, McGahan JP, Yacoub JH, McInnes M, Fung AW, Shanbhogue K, Lee J, Deshmukh S, Horvat N, Mitchell DG, Do RKG, Surabhi VR, Szklaruk J, Sirlin CB. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol (NY) 2018;43:2625-42. [PMID: 30155697 DOI: 10.1007/s00261-018-1744-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
66 Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, Kono Y, Do RK, Mitchell DG, Singal AG, Tang A, Sirlin CB. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 2018;289:816-30. [PMID: 30251931 DOI: 10.1148/radiol.2018181494] [Cited by in Crossref: 356] [Cited by in F6Publishing: 376] [Article Influence: 71.2] [Reference Citation Analysis]
67 Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, Kono Y, Sirlin CB, Tang A. LI-RADS 2017: An update. J Magn Reson Imaging 2018;47:1459-74. [PMID: 29626376 DOI: 10.1002/jmri.26027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
68 Soyer P. Agreement and observer variability. Diagnostic and Interventional Imaging 2018;99:53-4. [DOI: 10.1016/j.diii.2018.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
69 Santillan C, Chernyak V, Sirlin C. LI-RADS categories: concepts, definitions, and criteria. Abdom Radiol (NY) 2018;43:101-10. [PMID: 29038857 DOI: 10.1007/s00261-017-1334-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]